In latest turn to autoimmune therapies, Cullinan nabs $280M to join lupus space

At Cul­li­nan, im­munol­o­gy is quite lit­er­al­ly the new on­col­o­gy.

The biotech an­nounced Tues­day that it’s ex­pand­ing its pipeline from can­cer to in­clude im­munol­o­gy and chang­ing its name from Cul­li­nan On­col­o­gy to Cul­li­nan Ther­a­peu­tics. By do­ing so, the com­pa­ny is join­ing the au­toim­mune craze, be­com­ing the lat­est biotech to ei­ther add or piv­ot to­ward a pro­gram test­ing ground­break­ing can­cer treat­ments in lu­pus.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.